300 related articles for article (PubMed ID: 17530993)
21. HIV Resistance and Prevention of Mother-to-Child Transmission Regimen in HIV-Infected Infants in Northern Tanzania.
Dow DE; Schimana W; Nyombi BM; Mmbaga BT; Shayo AM; Bartlett JA; Massambu CG; Kifaro EG; Turner EL; DeMarco T; Cai F; Cunningham CK; Buchanan AM
AIDS Res Hum Retroviruses; 2017 Nov; 33(11):1107-1113. PubMed ID: 28797181
[TBL] [Abstract][Full Text] [Related]
22. Intrapartum tenofovir and emtricitabine reduces low-concentration drug resistance selected by single-dose nevirapine for perinatal HIV prevention.
Chi BH; Ellis GM; Chintu N; Cantrell RA; Sinkala M; Aldrovandi GM; Warrier R; Mbewe F; Nakamura K; Stringer EM; Frenkel LM; Stringer JS
AIDS Res Hum Retroviruses; 2009 Nov; 25(11):1099-106. PubMed ID: 19886836
[TBL] [Abstract][Full Text] [Related]
23. Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens.
Bunupuradah T; Ananworanich J; Chetchotisakd P; Kantipong P; Jirajariyavej S; Sirivichayakul S; Munsakul W; Prasithsirikul W; Sungkanuparph S; Bowonwattanuwong C; Klinbuayaem V; Petoumenos K; Hirschel B; Bhakeecheep S; Ruxrungtham K
Antivir Ther; 2011; 16(7):1113-21. PubMed ID: 22024527
[TBL] [Abstract][Full Text] [Related]
24. HIV-1 Drug Resistance by Ultra-Deep Sequencing Following Short Course Zidovudine, Single-Dose Nevirapine, and Single-Dose Tenofovir with Emtricitabine for Prevention of Mother-to-Child Transmission.
Samuel R; Julian MN; Paredes R; Parboosing R; Moodley P; Singh L; Naidoo A; Gordon M
J Acquir Immune Defic Syndr; 2016 Dec; 73(4):384-389. PubMed ID: 27327263
[TBL] [Abstract][Full Text] [Related]
25. Drug resistance mutations 18 months after discontinuation of nevirapine-based ART for prevention of mother-to-child transmission of HIV in Malawi.
Palombi L; Galluzzo CM; Andreotti M; Liotta G; Jere H; Sagno JB; Luhanga R; Mancinelli S; Amici R; Marazzi MC; Vella S; Giuliano M
J Antimicrob Chemother; 2015 Oct; 70(10):2881-4. PubMed ID: 26111981
[TBL] [Abstract][Full Text] [Related]
26. Emergence of drug resistant mutations after single dose nevirapine exposure in HIV-1 infected pregnant women in south India.
Rajesh L; Ramesh K; Hanna LE; Narayanan PR; Swaminathan S
Indian J Med Res; 2010 Nov; 132(5):509-12. PubMed ID: 21149999
[TBL] [Abstract][Full Text] [Related]
27. HIV-1 drug resistance and mother-to-child transmission.
Morris L; Pillay C; Gray G; McIntyre J
SADJ; 2001 Dec; 56(12):614-6. PubMed ID: 11887450
[TBL] [Abstract][Full Text] [Related]
28. Quantifying the impact of nevirapine-based prophylaxis strategies to prevent mother-to-child transmission of HIV-1: a combined pharmacokinetic, pharmacodynamic, and viral dynamic analysis to predict clinical outcomes.
Frank M; von Kleist M; Kunz A; Harms G; Schütte C; Kloft C
Antimicrob Agents Chemother; 2011 Dec; 55(12):5529-40. PubMed ID: 21947390
[TBL] [Abstract][Full Text] [Related]
29. Prevalence of nevirapine-associated resistance mutations after single dose prophylactic treatment among antenatal clinic attendees in north rift Kenya.
Kiptoo M; Ichimura H; Wembe RL; Ng'Ang'a Z; Mueke J; Kinyua J; Lagat N; Okoth F; Songok EM
AIDS Res Hum Retroviruses; 2008 Dec; 24(12):1555-9. PubMed ID: 19102687
[TBL] [Abstract][Full Text] [Related]
30. Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated.
Johnson JA; Li JF; Morris L; Martinson N; Gray G; McIntyre J; Heneine W
J Infect Dis; 2005 Jul; 192(1):16-23. PubMed ID: 15942889
[TBL] [Abstract][Full Text] [Related]
31. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.
Delaugerre C; Rohban R; Simon A; Mouroux M; Tricot C; Agher R; Huraux JM; Katlama C; Calvez V
J Med Virol; 2001 Nov; 65(3):445-8. PubMed ID: 11596076
[TBL] [Abstract][Full Text] [Related]
32. Reverse transcriptase mutations in Cambodian CRF01_AE isolates after antiretroviral prophylaxis against HIV Type 1 perinatal transmission.
Ly N; Phoung V; Min DC; Srey C; Kruy LS; Koum K; Chhum V; Glaziou P; Fleury HJ; Reynes JM
AIDS Res Hum Retroviruses; 2007 Dec; 23(12):1563-8. PubMed ID: 18160014
[TBL] [Abstract][Full Text] [Related]
33. Nevirapine resistance viral mutations after repeat use of nevirapine for prevention of perinatal HIV transmission.
Kuhn L; Sinkala M; Kankasa MP; Kasonde P; Thea DM; Aldrovandi GM
J Acquir Immune Defic Syndr; 2006 Jun; 42(2):260-2. PubMed ID: 16760802
[No Abstract] [Full Text] [Related]
34. Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission.
Jackson JB; Becker-Pergola G; Guay LA; Musoke P; Mracna M; Fowler MG; Mofenson LM; Mirochnick M; Mmiro F; Eshleman SH
AIDS; 2000 Jul; 14(11):F111-5. PubMed ID: 10983633
[TBL] [Abstract][Full Text] [Related]
35. Development of Nevirapine Resistance in Children Exposed to the Prevention of Mother-to-Child HIV-1 Transmission Programme in Maputo, Mozambique.
Antunes F; Zindoga P; Gomes P; Augusto O; Mahumane I; Veloso L; Valadas E; Camacho R
PLoS One; 2015; 10(7):e0131994. PubMed ID: 26161559
[TBL] [Abstract][Full Text] [Related]
36. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
Bacheler L; Jeffrey S; Hanna G; D'Aquila R; Wallace L; Logue K; Cordova B; Hertogs K; Larder B; Buckery R; Baker D; Gallagher K; Scarnati H; Tritch R; Rizzo C
J Virol; 2001 Jun; 75(11):4999-5008. PubMed ID: 11333879
[TBL] [Abstract][Full Text] [Related]
37. Women exposed to single-dose nevirapine in successive pregnancies: effectiveness and nonnucleoside reverse transcriptase inhibitor resistance.
Martinson NA; Morris L; Johnson J; Gray GE; Pillay V; Ledwaba J; Dhlamini P; Cohen S; Puren A; Steyn J; Heneine W; McIntyre JA
AIDS; 2009 Apr; 23(7):809-16. PubMed ID: 19287298
[TBL] [Abstract][Full Text] [Related]
38. Transmission of human immunodeficiency virus type 1 nevirapine resistance mutation K103N from a treatment-naive mother to her child.
Schmitz T; Kleinkauf N; Klempa B; Ringe H; Varnholt V; Grosch-Wörner I
Pediatr Infect Dis J; 2006 Mar; 25(3):275-6. PubMed ID: 16511398
[TBL] [Abstract][Full Text] [Related]
39. Impact of nevirapine (NVP) plasma concentration on selection of resistant virus in mothers who received single-dose NVP to prevent perinatal human immunodeficiency virus type 1 transmission and persistence of resistant virus in their infected children.
Chaix ML; Ekouevi DK; Peytavin G; Rouet F; Tonwe-Gold B; Viho I; Bequet L; Amani-Bosse C; Menan H; Leroy V; Rouzioux C; Dabis F
Antimicrob Agents Chemother; 2007 Mar; 51(3):896-901. PubMed ID: 17178792
[TBL] [Abstract][Full Text] [Related]
40. Surveillance of antiretroviral drug resistance mutations in untreated young children living in the Central African Republic.
Charpentier C; Gody JC; Tisserand P; Matta M; Péré H; Fournier J; Mbitikon O; Bélec L
Antivir Ther; 2011; 16(8):1347-50. PubMed ID: 22155917
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
